Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Successful Treatment of Primary Central Nervous System Lymphoma without Irradiation in Children: Single Center Experience

  • Yoon, Jong Hyung (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kang, Hyoung Jin (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Hyery (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Ji Won (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Park, June Dong (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Park, Kyung Duk (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Shin, Hee Young (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Ahn, Hyo Seop (Department of Pediatrics, Seoul National University College of Medicine)
  • Published : 2012.11.10
⟨ Previous Next ⟩

Abstract

Primary CNS lymphoma (PCNSL) is a very uncommon disease in children, and usually treated by chemotherapy, combined with focal or craniospinal radiotherapy (RT). However, adverse effects of RT are a concern. We evaluated the outcomes of childhood PCNSL, treated with systemic and intrathecal chemotherapy, but without RT. For fifteen years, six patients among 175 of non-Hodgkin lymphoma were diagnosed as PCNSL in Seoul National University Children's Hospital and we analyzed their medical records retrospectively. Their male:female ratio was 5:1, and median age was 10.1 yr. The primary sites were the sellar area in three patients, parietal area in one, cerebellum in one, and multiple areas in one. Their pathologic diagnoses were diffuse large B-cell lymphoma in three patients, Burkitt lymphoma in two, and undifferentiated B-cell lymphoma in one. Five were treated with the LMB96 treatment protocol, and one was treated with the CCG-106B protocol. None had RT as a first-line treatment. One patient had a local relapse and received RT and salvage chemotherapy, without success. No patient had treatment-related mortality. Their estimated 5-yr event-free and overall survival rates were both 83.3%. In conclusion, PCNSL is a rare disease in childhood, but successfully treated by chemotherapy without RT.

Keywords

References

  1. Abla O, Sandlund JT, Sung L, Brock P, Corbett R, Kirov I, Griffin TC, Blaser S, Weitzman S. A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation. Pediatr Blood Cancer 2006;47:880-5. https://doi.org/10.1002/pbc.20736
  2. Porto L, Kieslich M, Schwabe D, Yan B, Zanella FE, Lanfermann H. Central nervous system lymphoma in children. Pediatr Hematol Oncol 2005;22:235-46. https://doi.org/10.1080/08880010590921612
  3. Abla O, Weitzman S. Primary central nervous system lymphoma in children. Neurosurg Focus 2006;21:e8.
  4. Choi SY, Kim NK, Kwon SY, Han JW, Won SC, Lyu CJ. Experience of childhood non-Hodgkin lymphoma with central nervous system involvement at diagnosis. Clin Pediatr Hematol Oncol 2007;14:183-91.
  5. Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E, Doolittle ND, Baehring J, Pradhan K, Martin SE, et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res 2011;17:346-52. https://doi.org/10.1158/1078-0432.CCR-10-1161
  6. Blay JY, Ongolo-Zogo P, Sebban C, Carrie C, Thiesse P, Biron P. Primary cerebral lymphomas: unsolved issues regarding first line treatment, follow up, late neurological toxicity and treatment of relapses. Ann Oncol 2000;11(Suppl 1):39-44. https://doi.org/10.1093/annonc/11.suppl_1.S39
  7. Said JA, Waters BG, Cousens P, Stevens MM. Neuropsychological sequelae of central nervous system prophylaxis in survivors of childhood acute lymphoblastic leukemia. J Consult Clin Psychol 1989;57:251-6.
  8. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-60.
  9. Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Novak LJ, Pyesmany AF, Reaman GH, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol 1993;11:2234-42.
  10. Park ES, Kim H, Lee JW, Lim JY, Kang HJ, Park KD, Shin HY, Ahn HS. Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution. Korean J Hematol 2011;46:96-102. https://doi.org/10.5045/kjh.2011.46.2.96
  11. Yoon JH, Park JA, Kim EK, Kang HJ, Shin HY, Ahn HS. Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia. J Korean Med Sci 2009;24:281-8. https://doi.org/10.3346/jkms.2009.24.2.281
  12. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30. https://doi.org/10.3322/canjclin.56.2.106
  13. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Muenster group report. J Clin Oncol 2007;25:3915-22. https://doi.org/10.1200/JCO.2007.11.0700
  14. Hochberg FH, Baehring JM, Hochberg EP. Primary CNS lymphoma. Nat Clin Pract Neurol 2007;3:24-35. https://doi.org/10.1038/ncpneuro0395
  15. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999;43:199-201. https://doi.org/10.1023/A:1006290032052
  16. DeAngelis LM, Iwamoto FM. An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2006;311-6.
  17. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ. Non-Hodgkin's lymphoma of the brain: can high-dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17. https://doi.org/10.1016/0360-3016(92)90538-S
  18. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, et al. Results of a randomized international study of high-risk central nervous system B non- Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736-43.
  19. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144-50.
  20. Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neurooncol 2003;63:87-95. https://doi.org/10.1023/A:1023760824739
  21. Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003;21:2407-14. https://doi.org/10.1200/JCO.2003.01.135
  22. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomized phase 2 trial. Lancet 2009;374:1512-20. https://doi.org/10.1016/S0140-6736(09)61416-1
  23. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513-20. https://doi.org/10.1212/WNL.58.10.1513
  24. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-95. https://doi.org/10.1200/JCO.2003.04.056
  25. Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002;58:175-8. https://doi.org/10.1023/A:1016077907952
  26. Sung KH, Lee EH, Kim YZ. Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma. J Korean Med Sci 2011;26:551-60. https://doi.org/10.3346/jkms.2011.26.4.551
  27. Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, et al. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol 2011;70:163-9. https://doi.org/10.1002/ana.22360
  28. Ferreri AJ, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am 2005;19:629-49. https://doi.org/10.1016/j.hoc.2005.05.005
  29. Song MK, Chung JS, Joo YD, Lee SM, Oh SY, Shin DH, Yun EY, Kim SG, Seol YM, Shin HJ, et al. Clinical importance of Bcl-6-positive non-deepsite involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma. J Neurooncol 2011;104:825-31. https://doi.org/10.1007/s11060-011-0555-z

Cited by

  1. Primary Burkitt Lymphoma of the Fourth Ventricle in an Immunocompetent Young Patient vol.2014, pp.None, 2012, https://doi.org/10.1155/2014/630954
  2. Diagnosis and treatment of primary central nervous system lymphoma: A report of nine cases and literature review vol.9, pp.4, 2015, https://doi.org/10.3892/ol.2015.2903
  3. Rare Pediatric Non‐Hodgkin Lymphomas: A Report From Children's Oncology Group Study ANHL 04B1 vol.63, pp.5, 2012, https://doi.org/10.1002/pbc.25881
  4. Adolescent and young adult non‐Hodgkin lymphoma vol.173, pp.4, 2012, https://doi.org/10.1111/bjh.14074
  5. Management of primary central nervous system lymphoma in children vol.2016, pp.1, 2012, https://doi.org/10.1182/asheducation-2016.1.386
  6. Primary CNS Burkitt Lymphoma: A Case Report of a 55-Year-Old Cerebral Palsy Patient vol.2018, pp.None, 2012, https://doi.org/10.1155/2018/5869135
  7. A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost w vol.34, pp.9, 2012, https://doi.org/10.1007/s00381-018-3807-9
  8. A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy vol.54, pp.1, 2012, https://doi.org/10.1159/000495789
  9. Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents vol.3, pp.24, 2012, https://doi.org/10.1182/bloodadvances.2019001062
  10. Current trends in pediatric aggressive B-cell lymphomas treatment vol.16, pp.2, 2012, https://doi.org/10.17650/1818-8346-2021-16-2-21-27
  11. Primary central nervous system lymphoblastic B cell lymphoma located at cerebellum in a child: A case report and literature review vol.5, pp.4, 2012, https://doi.org/10.1002/ped4.12303